Having trouble viewing this email? View in your browser.

13 February 2018

Dear colleagues,

Please have a look at the new website of ESCMID’s journal Clinical Microbiology an Infection. The editorial office is happy to receive any feedback and suggestions for further improvement. 

Your ESCMID communications editors


Late-breaking abstract can be submitted from 15 February

The abstract submission for late-breaking abstracts will be open from 15 February to 1 March 2018. This year we will accept submission for the topics clinical trials, vaccine-preventable diseases and others. As a reminder, to be accepted, late breakers must contain novel data, which only became available after the end of November, when the regular submission deadline closed, be of outstanding scientific quality, fit the topics of the congress, and add value to the scientific programme.

› Read more

ESGICH, ESGITM contribute to transplant recommendations

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) and ESCMID Study Group for Infections in Travellers and Migrants (ESGITM) contributed to the Recommendations for Management of Endemic Diseases and Travel Medicine in Solid-Organ Transplant Recipients and Donors: Latin America. The clinical practice guideline is intended to guide clinicians caring for solid-organ transplant (SOT) donors, candidates and recipients regarding infectious diseases (ID) issues related to this geographical region, mostly located in the tropics. These recommendations are based on both systematic reviews of relevant literature and expert opinion from both transplant ID and travel medicine specialists. The guidelines provide recommendations for risk evaluation and laboratory investigation, as well as management and prevention of infection of the most relevant endemic diseases of Latin America. 

› Read more

CMI highlight: safety of tetravalent dengue vaccine efficacy

Researchers described the risk of hospital admission for confirmed dengue (VCD) and the risk of clinically severe hospitalised VCD occurring up to four years post first dose in three randomised clinical trials comparing tetravalent dengue vaccine to placebo. Overall, from year 1-4, 233 and 228 participants had ≥1 episode of hospitalised VCD in the vaccinated (N=22,603) and placebo groups (N=11,301), respectively. Among these, 48 and 47 cases, respectively, were classified as clinically severe. In children aged ≥9 years, 88 and 136 participants had ≥1 episode of hospitalised VCD in the vaccinated (N=17,629) and placebo groups (N=8,821), respectively. In vaccinated participants aged <9 years, particularly in those aged 2-5 years, there were more hospitalised VCD cases compared with the control participants in year 3 but not in year 4. The overall relative risks in those aged <9 years for year 1-4 was 0.786 with a higher protective effect in the 6-8-year-olds than in the 2-5-year-olds. The overall benefit-risk remained positive in those aged ≥9 years up to year 4, although the protective effect was lower in years 3 and 4 than in years 1 and 2 (open access).

› Read more
ESCMID Executive Office
P.O. Box 214
4010 Basel
Phone +41 61 5080 173
Visit us on LinkedIn Visit us on YouTube
The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add newsletter@escmid.org to your email program’s address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.